The treatment landscape for patients with advanced non-small cell lung cancer has evolved
greatly with the advent of immune checkpoint inhibitors. However, many patients do not …

Abstract Background Immune checkpoint inhibitors (ICIs) are standard of care in advanced
non-small cell lung cancer (NSCLC), however their status in patients with poor performance …

Background ATTRACTION-2 demonstrated that nivolumab improved overall survival (OS) vs
placebo in patients with advanced gastric cancer treated with≥ 2 chemotherapy regimens …

Background Immunotherapy has brought substantial benefit for patients with advanced non-
small cell lung cancer (NSCLC); however, resistance may occur, of which oligoprogression …

Background Nivolumab was the first immune checkpoint inhibitor approved for previously
treated advanced non–small cell lung cancer (NSCLC). Before its introduction in the market …

Lung cancer has attracted much attention because of its high morbidity and mortality
worldwide. The advent of immunotherapy approaches, especially the application of immune …

Purpose Immune checkpoint inhibitors are associated with clinical benefit in lung cancer.
However, response patterns to immunotherapy, including pseudoprogression and …

Background Immune checkpoint inhibitors (ICIs) represent a great breakthrough in the
treatment of advanced non-small cell lung cancer (aNSCLC). However, whether …

Purpose After progression to immunotherapy, the standard of care for non-small cell lung
cancer (NSCLC) was limited. Administration of the same or different immune checkpoint …

Background In this real-world multicenter study we addressed the activity of post-
progression anticancer treatments after first-line pembrolizumab in advanced non-small cell …